Garen G. Bohlin
Garen G. Bohlin's purchase track record
Garen G. Bohlin has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/12/2023 | KPTI | $50K | -42.5% | +12.4% | +16.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.
Transaction History
| KPTI | ▲ Buy | Grant | 15,508 | $0 | 5/21/2026 | View on chart |
| COLL | ▲ Buy | Grant | 8,741 | $0 | 5/14/2026 | View on chart |
| COLL | ▲ Buy | Option Exercise | 8,700 | $143K | 5/11/2026 | View on chart |
| COLL | ▼ Sell | Open Market | 8,700 | $323K | 5/11/2026 | View on chart |
| COLL | ▲ Buy | Grant | 9,791 | $0 | 5/15/2025 | View on chart |
| COLL | ▲ Buy | Grant | 7,693 | $0 | 5/16/2024 | View on chart |
| COLL | ▲ Buy | Option Exercise | 28,985 | $166K | 5/14/2024 | View on chart |
| COLL | ▼ Sell | Open Market | 28,985 | $936K | 5/14/2024 | View on chart |
| KPTI | ▲ Buy | Open Market | 41,140 | $50K | 9/12/2023 | View on chart |
| COLL | ▲ Buy | Grant | 9,792 | $0 | 5/18/2023 | View on chart |
| COLL | ▲ Buy | Grant | 14,035 | $0 | 5/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Karyopharm Reports Inducement Grant Under Nasdaq Rule
Karyopharm Therapeutics disclosed an inducement grant made under Nasdaq Listing Rule 5635(c)(4). This type of disclosure is typically required when a company offers equity compensation to a new employee or consultant to induce them to join the firm. The announcement is a standard corporate compliance update rather than a change in business operations or financial results.
Karyopharm Reports Inducement Grant Under Nasdaq Rule. Karyopharm Therapeutics disclosed an inducement grant made under Nasdaq Listing Rule 5635(c)(4). This type of disclosure is typically required when a company offers equity compensation to a new employee or consultant to induce them to join the firm. The announcement is a standard corporate compliance update rather than a change in business operations or financial results.